<DOC>
	<DOC>NCT01271933</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.</brief_summary>
	<brief_title>Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients must have fibromyalgia. Patients with other painful conditions cannot participate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>pain</keyword>
	<keyword>pregabalin</keyword>
	<keyword>Lyrica</keyword>
</DOC>